Clinical Trial Update: A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) [Phase 1]

View source ↗

Summary

Regeneron is evaluating ALN-CIDEB in a Phase 1 study in adults with metabolic dysfunction-associated steatotic liver disease or metabolic dysfunction-associated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis
• Metabolic Dysfunction-associated Steatotic Liver Disease

Drugs mentioned

• ALN-CIDEB

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis | Phase 1 | Status: RECRUITING